Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Targeted treatments to improve stem cell outcome: old and new drugs

Bone Marrow Transplantation volume 40, pages 1129–1137 (2007)Cite this article

Abstract

Thalidomide, lenalidomide and bortezomib have been approved for the treatment of relapsed or refractory multiple myeloma in the recent years. These agents are now being increasingly integrated into therapeutic regimens for newly diagnosed patients. First data are available on the promising activity of these novel agents in induction therapy, as well as maintenance treatment to improve outcome after stem cell transplantation. Whether these early results will lead to prolonged overall survival and thereby ultimately redefine the role of stem cell transplantation in first-line treatment of multiple myeloma will be one of the most important questions to be answered in the coming years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183–196.

    Article  CAS  PubMed  Google Scholar 

  2. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  CAS  PubMed  Google Scholar 

  3. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441.

    Article  PubMed  Google Scholar 

  4. D'Amato RJ, Loughnan MS, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kenyon BM, Browne F, D'Amato RJ . Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971–978.

    Article  CAS  PubMed  Google Scholar 

  6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.

    Article  CAS  PubMed  Google Scholar 

  7. Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79: 875–882.

    Article  CAS  PubMed  Google Scholar 

  8. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K . Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003; 40 (Suppl 4): 3–7.

    Article  CAS  PubMed  Google Scholar 

  9. Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumontet C et al. Thalidomide in patients with advanced multiple myeloma. Hematol J 2000; 1: 186–189.

    Article  CAS  PubMed  Google Scholar 

  10. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C . Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89–96.

    Article  CAS  PubMed  Google Scholar 

  11. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494.

    Article  CAS  PubMed  Google Scholar 

  12. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404–408.

    CAS  PubMed  Google Scholar 

  13. Blade J, Esteve J, Rosinol L, Perales M, Montoto S, Tuset M et al. Thalidomide in refractory and relapsing multiple myeloma. Semin oncol 2001; 28: 588–592.

    Article  CAS  PubMed  Google Scholar 

  14. Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001; 12: 987–990.

    Article  CAS  PubMed  Google Scholar 

  15. Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 408–414.

    CAS  PubMed  Google Scholar 

  16. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW . An UK myeloma forum phase II study of thalidomide; long-term follow-up and recommendations for treatment. Leuk Res 2003; 27: 909–914.

    Article  CAS  PubMed  Google Scholar 

  17. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34–39.

    Article  PubMed  Google Scholar 

  18. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950.

    CAS  PubMed  Google Scholar 

  19. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. M. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399–403.

    CAS  PubMed  Google Scholar 

  20. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991–995.

    Article  CAS  PubMed  Google Scholar 

  21. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112–117.

    Article  CAS  PubMed  Google Scholar 

  22. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863.

    Article  CAS  PubMed  Google Scholar 

  23. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001; 98: 3846–3848.

    Article  CAS  PubMed  Google Scholar 

  24. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831.

    Article  CAS  PubMed  Google Scholar 

  25. Facon T . Advances in the treatment of elderly patients with multiple myeloma. Clin Adv Hematol Oncol 2006; 4: 501–502.

    PubMed  Google Scholar 

  26. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R . Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.

    Article  CAS  PubMed  Google Scholar 

  27. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR . Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 2006; 24: 431–436.

    Article  CAS  PubMed  Google Scholar 

  28. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323.

    Article  CAS  PubMed  Google Scholar 

  29. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826–831.

    CAS  PubMed  Google Scholar 

  30. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39.

    Article  CAS  PubMed  Google Scholar 

  31. Breitkreutz I, Lokhorst HM, Raab MS, Holt BV, Cremer FW, Herrmann D et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21: 1294–1299.

    Article  CAS  PubMed  Google Scholar 

  32. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F ; et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    Article  CAS  PubMed  Google Scholar 

  33. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724–1732.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hussein MA . Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924–930.

    Article  CAS  PubMed  Google Scholar 

  35. Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs MJ et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10: 8170–8176.

    Article  CAS  PubMed  Google Scholar 

  36. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294.

    Article  CAS  PubMed  Google Scholar 

  37. Brinker BT, Waller EK, Leong T, Heffner LT, Redei I, Langston AA et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006; 106: 2171–2180.

    Article  CAS  PubMed  Google Scholar 

  38. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120–8125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269–3276.

    Article  CAS  PubMed  Google Scholar 

  40. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760.

    Article  CAS  PubMed  Google Scholar 

  41. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919–3924.

    Article  CAS  PubMed  Google Scholar 

  42. Hegenbart U, Schonland SO, Moehler TM, Benner A, Gerull S, Goerner M et al. Polychemotherapy in combination with thalidomide followed by autologous or allogeneic transplantation for rescue after autograft or induction therapy failure in patients with multiple myeloma. ASH Annual Meeting Abstracts 2006; 108: 3018.

    Google Scholar 

  43. van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107: 3415–3416.

    Article  CAS  PubMed  Google Scholar 

  44. Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005; 35: 165–169.

    Article  CAS  PubMed  Google Scholar 

  45. Kroger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361–3363.

    Article  PubMed  Google Scholar 

  46. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003; 32: 165–170.

    Article  CAS  PubMed  Google Scholar 

  47. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216.

    Article  CAS  PubMed  Google Scholar 

  48. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950–1961.

    Article  CAS  PubMed  Google Scholar 

  49. Lentzsch S, Le Blanc R, Podar K, Davies F, Lin B, Hideshima T et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41–44.

    Article  CAS  PubMed  Google Scholar 

  50. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530.

    Article  CAS  PubMed  Google Scholar 

  51. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067.

    Article  CAS  PubMed  Google Scholar 

  52. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Weber D, Wang M, Chen CI, Belch AR, Stadtmauer EA, Niesvizky R et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. ASH Annual Meeting Abstracts 2006; 108: 3547.

    Google Scholar 

  54. Dimopoulos MA, Anagnostopoulos A, Prince M, Harousseau JL, Dmoszynska A, Hellmann A et al. Lenalidomide (Revlimid) combination with dexamethasone (Dex) is more effective than Dex alone in patients with relapsed or refractory multiple myeloma. Haematologica 2006; 91: 194.

    Google Scholar 

  55. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust SR et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. ASH Annual Meeting Abstracts 2006; 108: 798.

    Google Scholar 

  57. Palumbo A, Falco P, Falcone A, Corradini P, Di Raimondo F, Giuliani N et al. Oral Revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. ASH Annual Meeting Abstracts 2006; 108: 800.

    Google Scholar 

  58. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole D, Greipp PR . A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern cooperative oncology group. ASH Annual Meeting Abstracts 2006; 108: 799.

    Google Scholar 

  59. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole D, Williams ME et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 2007. ASCO Annual Meeting Proceedings Part I 25, LBA8025. 2007; 25 (Suppl): 18.

  60. Richardson PG, Hideshima T, Anderson KC . Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003; 10: 361–369.

    Article  PubMed  Google Scholar 

  61. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    Article  CAS  PubMed  Google Scholar 

  62. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172.

    Article  CAS  PubMed  Google Scholar 

  63. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

    Article  CAS  PubMed  Google Scholar 

  64. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108: 2165–2172.

    Article  CAS  PubMed  Google Scholar 

  65. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783.

    Article  CAS  PubMed  Google Scholar 

  66. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498–1505.

    CAS  PubMed  Google Scholar 

  67. Rosinol L, Oriol A, Mateos MV, Sureda A, Diaz-Mediavilla J, Alegre A et al. Alternating bortezomib and dexamethasone as induction regimen prior to autologous stem-cell transplantation in newly diagnosed younger patients with multiple myeloma: results of a PETHEMA phase II trial. ASH Annual Meeting Abstracts 2006; 108: 3086.

    Google Scholar 

  68. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762.

    Article  CAS  PubMed  Google Scholar 

  69. Harousseau JL, Marit G, Caillot D, Casassus P, Facon T, Mohty M et al. VELCADE/Dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial. ASH Annual Meeting Abstracts 2006; 108: 56.

    Google Scholar 

  70. Schiller G, Sohn JP, Malone R, Bartone B, Habtemariam B, Paquette R et al. Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma. ASH Annual Meeting Abstracts 2007; 108: 5433.

    Google Scholar 

  71. Knop S, Hebart H, Kunzmann V, Angermund R, Einsele H . Bortezomib once weekly is well tolerated as maintenance therapy after less than a complete response to high-dose melphalan in patients with multiple myeloma. ASH Annual Meeting Abstracts 2007; 108: 5099.

    Google Scholar 

  72. Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006; 91: 837–839.

    CAS  PubMed  Google Scholar 

  73. Giaccone L, Sorasio R, Patriarca F, Mattei D, Montefusco V, Peccatori J et al. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment [in process citation]. Biol Blood Marrow Transplant 2007; 13: 479–499.

    Article  Google Scholar 

  74. Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: 770–775.

    Article  PubMed  Google Scholar 

  75. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    M S Raab, I Breitkreutz & K C Anderson

Authors
  1. M S Raab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Breitkreutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K C Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K C Anderson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raab, M., Breitkreutz, I. & Anderson, K. Targeted treatments to improve stem cell outcome: old and new drugs. Bone Marrow Transplant 40, 1129–1137 (2007). https://doi.org/10.1038/sj.bmt.1705829

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705829

Keywords

This article is cited by

Search

Advanced search

Quick links